$69.90
-0.32(-0.46%)
Mkt Cap $3.0B
$38.82
$82.51
52-Week Range
At a Glance
AI-generatedRevenue breakdown: Product (98.9%), License And Collaboration (0.9%), Development And Regulatory Milestone (0.2%).
8-K
Tarsus Pharmaceuticals, Inc. expanded its Board of Directors from seven to eight members and appointed David E.I. Pyott as a Class III director, effective February 18, 2026. Mr. Pyott was also appointed Chairperson of the Commercial Committee and member of the Nominating and Compensation Committees, with an initial equity grant valued at $540,000.$3.0B
Market Cap
$449M
Revenue
-$66M
Net Income
Employees323
Fundamentals
How The Business Makes Money
Revenue by Segment
Product98.9%($1.3B)
License And Collaboration0.9%($11M)
Development And Regulatory Milestone0.2%($3M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001819790
ISINUS87650L1035
CUSIP87650L103
Phone949 409 9820
Address15440 Laguna Canyon Road, Irvine, CA, 92618, US
SEC EDGAR